Prognostic importance of atrial fibrillation in heart failure according to time elapsed since diagnosis

Brian Schwartz; Morten Schou; Irene Maria Barrillas Lara; Kevin Monahan; Robert Helm; Lars Køber; Gunnar H. Gislason; Vasan S. Ramachandran; Christian Torp-Pedersen; Charlotte Andersson

doi:10.1016/j.hroo.2022.04.008

Prognostic importance of atrial fibrillation in heart failure according to time elapsed since diagnosis

Brian Schwartz, Morten Schou, Irene Maria Barrillas Lara, Kevin Monahan, Robert Helm, Lars Køber, Gunnar H. Gislason, Vasan S. Ramachandran, Christian Torp-Pedersen, Charlotte Andersson

Producción científica: Article › revisión exhaustiva

Idioma original	English (US)
Páginas (desde-hasta)	430-432
Número de páginas	3
Publicación	Heart Rhythm O2
Volumen	3
N.º	4
DOI	https://doi.org/10.1016/j.hroo.2022.04.008
Estado	Published - ago 2022
Publicado de forma externa	Sí

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Acceder al documento

10.1016/j.hroo.2022.04.008

Otros archivos y enlaces

Citar esto

@article{77b905ba9ac6494e8a3797fc5ea8432e,

title = "Prognostic importance of atrial fibrillation in heart failure according to time elapsed since diagnosis",

keywords = "Atrial fibrillation, Epidemiology, Heart failure, Mortality, Survival",

author = "Brian Schwartz and Morten Schou and {Barrillas Lara}, {Irene Maria} and Kevin Monahan and Robert Helm and Lars K{\o}ber and Gislason, {Gunnar H.} and Ramachandran, {Vasan S.} and Christian Torp-Pedersen and Charlotte Andersson",

note = "Funding Information: Dr Schwartz was funded by NIH StARR Grant 1R38HL143584 . Dr Ramachandran was supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine . Funding Information: Dr Schwartz was funded by NIH StARR Grant 1R38HL143584. Dr Ramachandran was supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine. Dr Schou has received lecture fees from Boehringer Ingelheim, AstraZeneca, and Novo Nordisk that are unrelated to the present work. Dr K{\o}ber reports lecture fees from Novartis, BMS, and AstraZeneca that are unrelated to the present work. Dr Torp-Pedersen has received study funding from Bayer and Novo Nordisk that is unrelated to the present work. All other authors declare that they have no conflicts of interest. All authors attest they meet the current ICMJE criteria for authorship. Consent was waived due ot the use of de-identified data. This study was exempted from ethical board approval, as the data from the registry used in this study were de-identified.",

year = "2022",

month = aug,

doi = "10.1016/j.hroo.2022.04.008",

language = "English (US)",

volume = "3",

pages = "430--432",

journal = "Heart Rhythm O2",

issn = "2666-5018",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Prognostic importance of atrial fibrillation in heart failure according to time elapsed since diagnosis

AU - Schwartz, Brian

AU - Schou, Morten

AU - Barrillas Lara, Irene Maria

AU - Monahan, Kevin

AU - Helm, Robert

AU - Køber, Lars

AU - Gislason, Gunnar H.

AU - Ramachandran, Vasan S.

AU - Torp-Pedersen, Christian

AU - Andersson, Charlotte

N1 - Funding Information: Dr Schwartz was funded by NIH StARR Grant 1R38HL143584 . Dr Ramachandran was supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine . Funding Information: Dr Schwartz was funded by NIH StARR Grant 1R38HL143584. Dr Ramachandran was supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine. Dr Schou has received lecture fees from Boehringer Ingelheim, AstraZeneca, and Novo Nordisk that are unrelated to the present work. Dr Køber reports lecture fees from Novartis, BMS, and AstraZeneca that are unrelated to the present work. Dr Torp-Pedersen has received study funding from Bayer and Novo Nordisk that is unrelated to the present work. All other authors declare that they have no conflicts of interest. All authors attest they meet the current ICMJE criteria for authorship. Consent was waived due ot the use of de-identified data. This study was exempted from ethical board approval, as the data from the registry used in this study were de-identified.

PY - 2022/8

Y1 - 2022/8

KW - Atrial fibrillation

KW - Epidemiology

KW - Heart failure

KW - Mortality

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85131119483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131119483&partnerID=8YFLogxK

U2 - 10.1016/j.hroo.2022.04.008

DO - 10.1016/j.hroo.2022.04.008

M3 - Article

C2 - 36097453

AN - SCOPUS:85131119483

SN - 2666-5018

VL - 3

SP - 430

EP - 432

JO - Heart Rhythm O2

JF - Heart Rhythm O2

IS - 4

ER -